{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:58:39Z","timestamp":1775455119516,"version":"3.50.1"},"reference-count":61,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Weight gain associated with antiretroviral therapy, particularly second\u2010generation integrase strand transfer inhibitors (INSTIs), is an increasingly recognized concern. However, literature remains mixed regarding whether these effects differ by sex\/gender. This scoping review aims to map the pattern, timing, severity and risk factors for weight gain among cis and trans women initiating or switching to second\u2010generation INSTIs, such as dolutegravir, bictegravir or cabotegravir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four databases (EMBASE, MEDLINE, Web of Science and CINAHL) were searched for studies reporting on weight gain after initiating or switching to second\u2010generation INSTIs in cis and trans women or mixed cohorts with data disaggregated by sex\/gender between 2010 and 2024. Three reviewers independently conducted the screening, and two reviewers extracted data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty articles were included. Most studies reported trends of increased and excessive weight gain in cis women compared to cis men taking dolutegravir or bictegravir\u2010based regimens, although findings were inconsistent and the extent of weight gain varied. Weight gain was particularly pronounced among treatment\u2010naive cis women, those of Black ethnicity or in African settings, and participants receiving dolutegravir in combination with tenofovir alafenamide. Studies on weight gain in cis women taking cabotegravir\u2010based regimens and trans women on any regimen were scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Second\u2010generation INSTIs, especially dolutegravir, appear to be associated with greater average and excessive weight gain among cis women, although this effect varies by setting, regimen and clinical context. Further research, especially in diverse populations, is needed to explore underlying mechanisms, determine risk factors and evaluate these trends in newer antiretroviral medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70190","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:16:17Z","timestamp":1768968977000},"page":"513-532","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex and gender differences in weight gain associated with second\u2010generation integrase strand transfer inhibitors: A scoping review"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4216-7779","authenticated-orcid":false,"given":"Tahani","family":"Shraida","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences Simon Fraser University  Burnaby British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Kwak","sequence":"additional","affiliation":[{"name":"School of Population and Public Health University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowan","family":"Patterson","sequence":"additional","affiliation":[{"name":"Faculty of Biological Sciences Simon Fraser University  Burnaby British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Undarmaa","family":"Enkhbat","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences Simon Fraser University  Burnaby British Columbia Canada"},{"name":"School of Public Health Mongolian National University of Medical Sciences  Ulaanbaatar Mongolia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0997-0137","authenticated-orcid":false,"given":"Caitlin","family":"Chew","sequence":"additional","affiliation":[{"name":"Oak Tree Clinic, BC Women's Hospital  Vancouver British Columbia Canada"},{"name":"Department of Pharmacy Children's &amp; Women's Health Centre of British Columbia, Lower Mainland Pharmacy Services  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Small","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences Simon Fraser University  Burnaby British Columbia Canada"},{"name":"British Columbia Centre on Substance Use  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"King","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences Simon Fraser University  Burnaby British Columbia Canada"},{"name":"Oak Tree Clinic, BC Women's Hospital  Vancouver British Columbia Canada"},{"name":"Women's Health Research Institute  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad611"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0147"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu040"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25484"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_2_11_7_1","article-title":"Weight and lipid changes in phase 3 cabotegravir and rilpivirine long\u2010acting trials","author":"Patel P","journal-title":"CROI Conference."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003584"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(20)30238\u20101"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2239661"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae007"},{"key":"e_1_2_11_12_1","first-page":"2","article-title":"Weight gain plateaus at 24\u2010months follow\u2010up for ART\u2010experienced patients that switched to dolutegravir in a Nigerian early adopter cohort","volume":"23","author":"Campbell J","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260063"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_11_15_1","unstructured":"PROSPERO. Accessed May 16 2025https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024521635"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00842\u201009"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102458\u201012\u2010234"},{"key":"e_1_2_11_18_1","unstructured":"Address HIV\u2010Associated Comorbidities Coinfections & Complications | National Institutes of Health. Accessed November 11 2025https:\/\/oar.nih.gov\/hiv\u2010policy\u2010and\u2010research\/research\u2010priorities\u2010overview\/address\u2010hiv\u2010associated\u2010comorbidities\u2010coinfections\u2010complications"},{"key":"e_1_2_11_19_1","unstructured":"Covidence \u2013 Better systematic review management. Covidence. Accessed June 4 2025https:\/\/www.covidence.org\/"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18\u20100850"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002533"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12860"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003087"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25899"},{"issue":"1","key":"e_1_2_11_25_1","first-page":"51","article-title":"Dolutegravir with recycled nRTIs is noninferior to PI\u2010based ART: VISEND trial","volume":"30","author":"Mulenga LB","year":"2022","journal-title":"Top Antivir Med"},{"issue":"1","key":"e_1_2_11_26_1","article-title":"Long\u2010Term outcomes of dolutegravir and efavirenz\u2010400 as first\u2010line ART in Cameroon","volume":"30","author":"Ngole\u2010Etame MM","year":"2022","journal-title":"Top Antivir Med"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac949"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad581"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2023.102807"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1333"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/09564624231179767"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003173"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2242250"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13617"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26216"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz491"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13373"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003070"},{"issue":"3","key":"e_1_2_11_39_1","first-page":"31","article-title":"Weight gain after switching from efavirenz\/emtricitabine\/tenofovir disoproxil fumarate (EFV\/FTC\/TDF) to bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in HIV\u2010suppressed patients","volume":"22","author":"Cicalini S","year":"2021","journal-title":"HIV Med."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002731"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13493"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13183"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13501"},{"issue":"2","key":"e_1_2_11_44_1","first-page":"279","article-title":"Weight gain following switch to dolutegravir among adult HIV cohorts in West Africa","volume":"31","author":"Tiendrebeogo T","year":"2023","journal-title":"Top Antivir Med"},{"key":"e_1_2_11_45_1","unstructured":"TiraboschiJCrusellsMJ DomingoP661 \u2013 Switch to DTG\/3TC vs B\/F\/TAF (PASO\u2010DOBLE Study): Efficacy and Weight Changes by Predefined Subgroups. CROI Conference. Accessed May 20 2025https:\/\/www.croiconference.org\/abstract\/1035-2025\/"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa195"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.36469\/001c.24535"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2023.10.012"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa177"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz853"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae540"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002742"},{"key":"e_1_2_11_53_1","article-title":"Differential BMI changes following PI\u2010 and INSTI\u2010based ART initiation by sex and race","author":"Bedimo R","journal-title":"CROI Conference."},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0197"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2022.0185"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12961"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279996"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad178"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2022.31825"},{"key":"e_1_2_11_60_1","article-title":"Dolutegravir targets the hypothalamus to suppress energy expenditure via estrogen receptor","author":"Jung I","journal-title":"CROI Conference."},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.70817"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103246"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70190","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:10:11Z","timestamp":1775452211000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/hiv.70190"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70190","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2025-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}